Back

Discussant review: Clinical effects of anacetrapib in people with established vascular disease: Results of the Randomized EValuation of the Effects of Anacetrapib through Lipid-modification (HPS3/TIMI55-REVEAL) trial

29 August 2017 (08:40 - 08:45)
Organised by:
Congress Presentation Part of: Hot Line: Late-Breaking Clinical Trials 4 Lipids (Epidemiology and Prevention) ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor John Chapman

Pitie Salpetriere APHP University Hospital, Paris (France)

12 More presentations in this session

Presentation thumbnail
Clinical effects of anacetrapib in people with established vascular disease: Results of the Randomized EValuation of the Effects of Anacetrapib through Lipid-modification (HPS3/TIMI55-REVEAL) trial
Professor M. Landray (Oxford, GB)
Slides Video
Presentation thumbnail
Panel discussion.
Video
Presentation thumbnail
Does intensive treat-to-target LDL-C lowering therapy using statin in patients of diabetic retinopathy reduce cardiovascular events?: the EMPATHY study
Professor H. Itoh (Tokyo, JP)
Slides Video
Presentation thumbnail
Discussant review: Does intensive treat-to-target LDL-C lowering therapy using statin in patients of diabetic retinopathy reduce cardiovascular events?: the EMPATHY study
Professor E. Prescott (Copenhagen, DK)
Slides Video
Presentation thumbnail
Panel discussion.
Video

Access the full session

Session thumbnail
Hot Line: Late-Breaking Clinical Trials 4

The Event

Event poster

ESC Congress 2017

29 August 2017 08:40 CET
You may be interested in
thumbnail
Congress Session
Innovating the clinical management of LDL-c: exploring CETP as therapeutic target
30 August 2024
thumbnail
ESC TV Today
Episode 26: Lp(a): the future starts now - Myocardial infarction in older age and frailty
6 November 2025
thumbnail
Webinar
Post-ACS management of dyslipidaemia: tips and tricks from real world experiences
16 December 2020
thumbnail
Congress Presentation
Carotid plaques stabilization and regression with evolocumab
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources